readthroughSign in
Nov 9, 2026Trial update3 fact check notes

RenJi Hospital registers long-term follow-up study for Gracell's GC012F in multiple myeloma

A new observational registry entry will track CAR-T patients previously dosed with GC012F Injection for up to 15 years, with status listed as enrolling by invitation.

  • The study is an open-label, multicenter, observational trial sponsored by RenJi Hospital, with Gracell Biotechnologies (Shanghai) Co., Ltd., AstraZeneca Global R&D (China) Co., Ltd., and AstraZeneca Global R&D (Beijing) Co., Ltd. listed as collaborators. The record's status is enrolling by invitation, first posted 2026-09-22 and last updated 2026-11-09.
  • Enrollment is estimated at 40 participants, all of whom previously received GC012F Injection in an investigator-initiated trial1 for multiple myeloma. No additional study drug will be administered in this study.1
  • Data collection is planned for 15 years from the time the subject received GC012F Injection infusion1, covering specific adverse events, overall survival, progression-free survival, duration of response, objective response rate, and CAR gene insertion site testing.

Fact check notes

  • Checker's noteThe claim that the registry item 'appeared this week' is not supported by the source, which only provides posting/update dates without specifying a 'this week' timeframe.
  • Sentence removedOne registry item appeared for Gracell Biotechnologies' GC012F Injection this week.unsupported: The source gives posting/update dates but does not state the item appeared 'this week'; this timing claim is not verifiable from the source.
  • Sentence removedIt is designed to evaluate the long-term safety, efficacy, and in vivo pharmacokinetic persistence of CAR-T cells in subjects treated with GC012F Injection.copied source wording

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Where the check questioned a sentence, its note is shown above. Not investment advice.